Introduction {#sec1_1}
============

Eosinophilic esophagitis (EoE) is an antigen/immune-mediated, chronic inflammatory condition of the esophagus defined by symptoms of esophageal dysfunction and a marked eosinophilic infiltrate in the esophageal mucosa \[[@B1]\]. For the diagnosis of EoE, one must have at least one biopsy specimen with ≥15 eosinophils per high-power field after a high-dose proton pump inhibitor trial and symptoms related to esophageal dysfunction. These range from feeding difficulties, vomiting and abdominal pain in infants and toddlers to dysphagia and food impactions in older patients. Common endoscopic findings in EoE include linear furrows, fixed or transient esophageal rings, whitish exudates, edema, diffuse esophageal narrowing and crepe paper esophagus, the term given to mucosa which is thin, fragile and tears easily \[[@B1]\]. EoE can be treated with topical corticosteroids such as fluticasone or oval viscous budesonide, and in rare cases with systemic corticosteroids if there is severe EoE manifested by a small-caliber esophagus, weight loss or hospitalization \[[@B1]\].

Systemic inflammatory states are known risk factors for venous thromboembolism (VTE), including inflammatory bowel disease \[[@B2], [@B3], [@B4]\] and rheumatoid arthritis \[[@B5]\] through a variety of proposed mechanisms including inflammation-mediated hypercoagulability, upregulation of procoagulant proteins and downregulation of anticoagulant proteins. EoE is currently thought to cause local rather than systemic inflammation \[[@B1]\]. However, in this report we describe a case of pulmonary embolism (PE) without evidence of deep venous thrombosis in a patient with severe EoE. This case raises the question of whether disease states with local inflammation alone might also be associated with VTE, and in this article, we explore potential mechanisms by which patients with EoE might develop venous thromboembolic disease.

Case Report {#sec1_2}
===========

A 33-year old man with a known history of EoE presented for endoscopy for recurrent dysphagia. He was diagnosed 2 years prior to presentation as per consensus guidelines \[[@B1]\] after emergent upper endoscopy for an acute food impaction. He reported a life-long history of dysphagia with intermittent food impactions as well as allergic rhinitis and sinusitis. He had no other medical problems and a previous complete blood count was normal with no evidence of peripheral eosinophilia (white blood count 5.3 × 10^9^/l, hemoglobin 15.4 g/dl, platelets 230 × 10^9^/l, normal differential with absolute eosinophil count 0.2 × 10^9^/l). His disease course had been complicated by an esophageal stricture which was 12 mm in narrowest diameter (fig. [1a](#F1){ref-type="fig"}), requiring multiple balloon dilations up to 15 mm in diameter. Despite treatment with high-dose swallowed fluticasone (880 μg twice daily) and then oral viscous budesonide (1 mg twice daily) over a 9-month period, he had ongoing dysphagia and persistently high levels of esophageal eosinophilia on follow-up biopsy (\>100 eosinophils per high-power field) (fig. [1b](#F1){ref-type="fig"}). His dose of oral viscous budesonide was increased to 2 mg orally twice daily and he was on this dose for 3 months prior to presentation. He was also treated with omeprazole 20 mg daily. Six weeks prior to presentation, in an effort to treat his refractory esophageal eosinophilia and dysphagia, he was prescribed an oral prednisone taper: 40 mg once daily for 2 weeks, then 30 mg once daily for one week, then 20 mg once daily for one week, then 10 mg once daily for 2 weeks and finally 5 mg once daily for 2 weeks. This taper was completed 1 week prior to his endoscopy and he reported some improvement in his dysphagia.

At the time of endoscopy, he complained of dyspnea and pleuritic chest pain over the preceding 48 h, had focal tenderness of the left lower rib cage, and was febrile (101.2°F). He was tachypneic but had normal oxygen saturation on pulse oximetry. Chest X-ray showed atelectasis and a possible infiltrate in the left lower lobe. Initial laboratory data were unremarkable (table [1](#T1){ref-type="table"}), with the exception of an elevated D-dimer at 482 ng/ml (reference range: 0--229 ng/ml). CT angiography of the chest demonstrated filling defects within the left upper lobe and left and right lower lobe segmental and subsegmental pulmonary arterial branches, consistent with PE (fig. [2a--c](#F2){ref-type="fig"}). Patchy opacities at the left lung base were felt to represent pulmonary infarct (fig. [2d](#F2){ref-type="fig"}). Doppler ultrasound of both legs was negative for deep venous thrombosis. He was started on a heparin drip and subsequently transitioned to warfarin. Thrombophilia workup (factor V Leiden, prothrombin 20210 gene mutation, protein C, protein S, and antithrombin activities, beta-2-glycoprotein I and anticardiolipin antibodies, and lupus anticoagulant) was negative for inherited and acquired hypercoagulable states (table [2](#T2){ref-type="table"}). His only potential risk factors for VTE were grade 1 obesity, with a body mass index of 30.3 kg/m^2^, and recent steroid use. There had been no preceding trauma, immobility, surgery or long-distance travel. Thus, this was interpreted as an unprovoked (idiopathic) VTE. He did not have peripheral blood eosinophilia, but did have an elevated IgE level of 242 kU/l (reference range: mean 13.2 kU/l, +1SD 41, +2SD 127). He recovered well with no sequelae, but is being continued on long-term anticoagulation given his risk of recurrent VTE.

Discussion {#sec1_3}
==========

In certain chronic inflammatory and autoimmune disease states, there appears to be increased risk for VTE. These include vasculitides, rheumatoid arthritis, systemic sclerosis, immune thrombocytopenic purpura, systemic lupus erythematosus, polymyositis and dermatomyositis \[[@B5]\]. Patients with inflammatory bowel disease have a 2- to 3-fold increased risk of VTE when compared to controls \[[@B2], [@B3]\]. This risk is increased in patients with active disease and to a lesser degree in patients in remission \[[@B2]\], and there is also an increased risk of recurrent VTE \[[@B4]\]. Celiac disease, also characterized by chronic mucosal inflammation, has been associated with an increased risk of VTE in some studies \[[@B6]\], however the data are less conclusive than in inflammatory bowel disease and there is evidence that the risk might not be elevated \[[@B7]\].

As in inflammatory bowel disease and celiac disease, there is chronic mucosal inflammation in EoE. While there has been a case report of VTE in a patient with hypereosinophilia \[[@B8]\] and in a patient with eosinophilic gastroenteritis \[[@B9]\], to our knowledge there have been no previous reports of VTE occurring in patients with EoE. In the patient presented here, there was persistent and severe esophageal eosinophilia that was refractory to topical steroid therapy and resulted in active symptoms of dysphagia and recurrent esophageal strictures requiring repeated dilations. While the PE could have been a coincidence as a sporadic occurrence, possibly related to mild obesity or low-dose steroid use, it is intriguing to hypothesize that the chronic inflammation may have been a risk factor for VTE.

How might inflammation play a role in VTE in EoE, and are there any clues from patients with Crohn\'s and ulcerative colitis with concomitant VTE? The mechanisms behind the increased risk of thrombosis in patients with inflammatory bowel disease are as yet not well defined. Inflammatory bowel disease may be a hypercoagulable state due to inflammatory-mediated upregulation of procoagulants, downregulation of anticoagulants or suppression of fibrinolysis \[[@B5], [@B10]\]. Patients with inflammatory bowel disease have increased fibrinogen, and there are reports of decreased protein S activity \[[@B11]\], which could contribute to acquired thrombophilia. However, other evidence does not demonstrate the same procoagulant profile \[[@B12]\]. Other possible mechanisms include inflammation-mediated platelet activation \[[@B10]\] and corticosteroid use \[[@B3], [@B5]\]. These abnormalities might not be expected to be present in most patients with EoE, given the absence of the systemic inflammation that is typically seen in inflammatory bowel diseases. However, there is some preliminary evidence that increased markers of eosinophil activity (e.g. eosinophil-derived neurotoxin and eotaxin-3) can be detected in the blood of patients with EoE, suggesting some systemic activity or effect \[[@B13]\].

It is possible that hypereosinophilia itself may be associated with hypercoagulability. One potential mechanism is that major basic protein, a protein found in eosinophilic cytoplasmic granules, inhibits the ability of thrombomodulin to bind to thrombin and activate protein C \[[@B14]\]. Activated protein C acts as an anticoagulant \[[@B8], [@B14]\]; thus, if hypereosinophilia leads to inhibition of thrombomodulin, the balance might be shifted towards a procoagulant state. In addition, IgE may play a role. Patients with asthma and allergic rhinitis were noted to have platelet activation when exposed to dust mite allergens \[[@B15]\]. It is hypothesized that this process is mediated by antigen-specific IgE. Our patient did have a slightly elevated IgE level. However, although there is a strong association between EoE and atopic diseases, there are no reports documenting an association between atopic diseases themselves and VTE.

In conclusion, EoE is an increasingly recognized condition characterized by chronic mucosal inflammation and infiltration of the esophageal epithelium with eosinophils. We present the first case of a patient with EoE who developed a PE in the absence of other strong risk factors for VTE. This case highlights the importance of considering the diagnosis of VTE in the appropriate clinical setting in patients with EoE, and also raises the question of whether the PE in this patient was coincidental or a consequence of active EoE with severe and uncontrolled esophageal inflammation. If it is the latter, the mechanism is unclear, and the absolute risk of VTE in patients with EoE is unknown. Additional studies will be required to examine the prevalence of VTE in EoE to determine whether EoE is truly a risk for VTE and, if such an association is determined, explore the potential mechanisms of hypercoagulability in EoE.
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![Endoscopic and histologic images showing active EoE. **a** The endoscopic view shows a narrow-caliber and strictured proximal esophagus with prominent rings, linear furrows, and decreased mucosal vascularity. **b** The histologic view (40×) of the esophageal biopsy specimen demonstrates a marked eosinophilic infiltrate in the mucosa as well as basal layer hyperplasia and spongiosis.](crg-0007-0082-g01){#F1}

![CT angiography demonstrating multiple segmental pulmonary emboli and subsequent pulmonary infarct. **a** A filling defect consistent with PE is noted in the left lower lobe segmental artery (arrow). **b** A filling defect consistent with PE is noted in the right lower lobe segmental artery (arrow). **c** Another filling defect noted in the left lower lobe segmental artery (arrow). **d** Patchy opacities seen in left lower lobe most consistent with pulmonary infarct.](crg-0007-0082-g02){#F2}

###### 

Laboratory data obtained in a patient with PE and EoE

  Laboratory study                           Value     Reference range
  ------------------------------------------ --------- -----------------
  Sodium, mmol/l                             138       135--145
  Potassium, mmol/l                          4.4       3.5--5
  Chloride, mmol/l                           100       98--107
  CO~2~, mmol/l                              29        22--30
  Blood urea nitrogen, mg/dl                 13        7--21
  Creatinine, mg/dl                          1.11      0.70--1.30
  Glucose, mg/dl                             92        65--179
  Creatine kinase, U/l                       48        70--185
  Creatine kinase MB, ng/ml                  \<0.2     0.0--6.0
  Troponin I, ng/ml                          \<0.034   0.000--0.034
  Prothrombin time, s                        11.7      9.7--12.6
  International normalized ratio             1.1       
  Activated partial thromboplastin time, s   26.9      24.1--32.5
  D-dimer, ng/ml                             482       0--229
  White blood cell count, ×10^9^/l           11.7      4.5--11
  Absolute neutrophils, ×10^9^/l             9.4       2.0--7.5
  Absolute eosinophils, ×10^9^/l             0.1       0.0--0.4
  Absolute lymphocytes, ×10^9^/l             1.5       1.5--5.0
  Absolute monocytes, ×10^9^/l               0.7       0.2--0.8
  Absolute basophils, ×10^9^/l               0.0       0.0--0.1
  Hemoglobin, g/dl                           17.1      13.5--17.5
  Hematocrit, %                              46.1      41.0--53.0
  Platelet count, ×10^9^/l                   247       150--440

Laboratory evaluation at the time of presentation demonstrated normal electrolytes, cardiac enzymes, coagulation studies and complete blood count with differential. D-dimer was noted to be elevated to more than twice the upper limit of normal.

###### 

Laboratory data from hypercoagulability workup obtained in a patient with PE and EoE

  Laboratory study                                 Value      Reference range
  ------------------------------------------------ ---------- -----------------
  Factor V 1691G\>A (factor V Leiden)              negative   negative
  Prothrombin 20210 G\>A gene mutation             negative   negative
  Protein C activity, % of normal                  117        68--170
  Protein S activity, % of normal                  101        64--147
  Free protein S, % of normal                      140        63--161
  Antithrombin III activity, % of normal           97         83--123
  Beta-2-glycoprotein I (IgA, IgM, IgG), U/ml      \<4.0      \<10
  Anticardiolipin antibody, IgG, GPL               4          0--23
  Anticardiolipin antibody, IgM, MPL               5          0--11
  Lupus activated partial thromboplastin time, s   41.0       35.4--50.8
  Dilute Russell\'s viper venom time, s            39.3       0--47.1

Hypercoagulability workup was within normal limits.
